Label-free identification and characterization of living human primary and secondary tumour cells by Tsikritsis, Dimitrios et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Label-free identification and characterization of living human
primary and secondary tumour cells
Citation for published version:
Tsikritsis, D, Richmond, S, Stewart, P, Elfick, A & Downes, A 2015, 'Label-free identification and
characterization of living human primary and secondary tumour cells' Analyst, vol. 140, no. 15, pp. 5162-
5168. DOI: 10.1039/c5an00851d
Digital Object Identifier (DOI):
10.1039/c5an00851d
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Analyst
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Analyst
PAPER
Cite this: Analyst, 2015, 140, 5162
Received 29th April 2015,
Accepted 5th June 2015
DOI: 10.1039/c5an00851d
www.rsc.org/analyst
Label-free identiﬁcation and characterization of
living human primary and secondary tumour cells
Dimitrios Tsikritsis,a Susanna Richmond,b Patrick Stewart,c Alistair Elﬁcka and
Andrew Downes*a
We used three label-free minimally invasive methods to characterize individual cells derived from primary
and secondary tumours from the same patient, and of the same type – colorectal. Raman spectroscopy
distinguished cells by their biochemical ‘ﬁngerprint’ in a vibrational spectrum with 100% accuracy, and
revealed that the primary cell line contains more lipids and alpha-helix proteins, whereas the secondary
cell line contains more porphyrins and beta-sheet proteins. Stimulated Raman scattering (SRS)
microscopy distinguished cells in chemically-speciﬁc images of CH2 bonds which revealed lipid droplets
in secondary tumour cells. Atomic force microscopy (AFM) was used to distinguish cells with 80% accu-
racy by measuring their elasticity – secondary tumour cells (SW620) are around 3 times softer than
primary ones (SW480). As well as characterizing the physical and biochemical diﬀerences between cell
lines in vitro, these techniques oﬀer three novel methods which could potentially be used for diagnosis –
to assign a tumour as primary or secondary.
1. Introduction
Metastasis – the spreading of cancer from one organ to
another – results in secondary tumours which are responsible
for 90% of deaths from cancer.1 To reduce death rates, it is
essential to understand metastasis and characterize primary
and secondary tumours. Primary tumours possess diﬀerent
genetic profiles2,3 from secondary tumours, so this is used to
clinically diagnose whether a tumour is primary or secondary
in nature.
Receptor biomarkers are specific to a cancer type,4 and
these biomarkers of a secondary tumour should remain
unchanged from the primary source. Alternatively, some bio-
markers may be specific to metastasis.5 So, in future it may be
possible to distinguish primary and secondary tumours with
MRI or CT contrast agents, such as nanoparticles coated with
such antibodies.
However, there is currently no label-free method to dis-
tinguish primary from secondary tumours. Label-free methods
which are real time would improve treatment over genetic
tests, as they would be performed during surgery in vivo or on
excised tissue. As well as being directly relevant to optimum
patient treatment, such label-free methods may also oﬀer an
improvement in understanding the mechanism of metastasis.
Raman spectroscopy6 is a form of optical spectroscopy
which does not require labels like fluorophores. A well-defined
laser frequency excites vibrational bonds in biomolecules
(such as C–C, C–H, CvO). A small proportion of the laser light
is absorbed by the molecule, then re-emitted at a lower fre-
quency. The frequency shift of the light is equal to the fre-
quency of the molecular vibration. When the scattered light is
passed through a spectrometer, a spectrum of peaks occurs at
characteristic frequency shifts which correspond to the
vibrational bonds. This won C.V. Raman the Nobel prize in
1930. The technique is applicable to individual living cells7,8
by focussing the laser within a microscope, and the Raman
spectrum can be considered as a biochemical fingerprint of
the cell. Raman spectroscopy has been successfully applied to
cancer cells and tissues to distinguish between cancerous and
healthy tissue or cells.9–15
Raman spectroscopy has also been applied to the study of
metastasis in several ways. Firstly, cells or tissue from a
primary tumour are compared with a metastatic tumour
spread to a diﬀerent organ.16 Secondly, unrelated cell lines
which cause metastasis are compared with those which do
not.17,18 Thirdly, diﬀerent patients with either a primary or
secondary tumour have been compared.19 Fourthly, primary
tumours were compared between patients who went on to
develop metastasis with those who did not.20 Finally, Raman
spectroscopy has distinguished between benign, primary
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and secondary malignancies in lymph nodes from a variety of
patients.21 Until now, there has not been a Raman compari-
son of primary (non-metastatic) and secondary (metastatic)
tumour cells from the same organ and the same patient, such
as those in this study. This is crucial to separating out the
single diﬀerence – the primary or secondary nature of the
tumour cells – from other variations such as organ, or person.
Atomic Force Microscopy (AFM)22,23 is a technique for
nanoscale topographic profiling of a surface, using a cantilever
with a tip of radius ∼10 nm. However, it can also be used to
measure the Elasticity (Young’s modulus) of a compressible
surface.24 It was first applied to cancer as a comparison of cell
elasticity between metastatic and healthy cells.25,26 It has since
been extended to staging the disease in mice breast tissue as
early, normal, benign, or invasive; and for comparison of
primary breast vs. metastatic lung tissue in mice.27 AFM has
also compared low and highly metastatic cells in vitro.28,29 The
technique measures lower average values of elasticity for meta-
static cells,27 and for those with high potential for meta-
stasis.28,29 Until now, there has been no comparison of primary
(non-metastatic) and secondary (metastatic) tumour cell lines
from the same organ and the same patient, and no quantitat-
ive measure of the accuracy of AFM to assign cells as meta-
static or non-metastatic.
Raman microscopy can be performed by raster scanning a
sample and acquiring a Raman spectrum at each pixel, but is
slow – around 2 seconds per pixel.30 It has been applied to
cancer tissue to characterize regions, such as Basal Cell Carci-
noma in skin,11,30 and malignant from normal lung tissue.31
However, far more rapid versions of Raman microscopy exist
which exploit multi-photon excitation, namely coherent anti-
Stokes Raman scattering (CARS) microscopy32 and stimulated
Raman scattering (SRS) microscopy33 which is considered as
an improvement over CARS microscopy due to its background-
and artefact-free images. CARS has been used to identify
regions as cancerous – oﬀering label-free versions of Haema-
toxylin and Eosin stains with excellent correlation.34,35 CARS
has also been used to investigate metastatic cells – measuring
uptake of lipids,36 and observing them in the bloodstream due
to their higher lipid content.37 SRS has been applied to imaging
cancer tissue,38 and successfully identified tumour margins
by imaging symmetric and anti-symmetric CH2 vibrations (at
2845 cm−1 and 2930 cm−1 respectively). It has also been applied
to a primary brain tumour and its metastasis into breast
tissue,38 but there was no clear diﬀerence between images.
AFM, Raman spectroscopy, and SRS microscopy are all tech-
niques which are able to distinguish cancerous from healthy
cells and tissue. So all these techniques will be applied to
primary and secondary cancer cells in this study, to determine
their eﬀectiveness. To distinguish only between the primary
and secondary nature of the cells, rather than any other diﬀer-
ences, we used the colorectal cell lines SW480 (primary) and
SW620 (secondary). This crucially removes any diﬀerences
related to tumour environment (organ). This pair of cell lines
is also from the same patient, so any diﬀerences will strictly be
attributed solely to their primary or secondary nature.39
2. Materials and methods
2.1 Cell culture
SW480 and SW620 cell lines were acquired from the American
Type Culture Collection (ATCC), and have both been cultured
for less than 6 months. They were both cultured in Dulbecco’s
Modified Eagle Medium (Gibco 41966), supplemented with
10% Foetal Calf Serum (Gibco 16140) without antibiotics. Cells
were plated onto glass-bottom dishes (WPI Fluorodish FD35)
for stimulated Raman scattering (SRS) microscopy and atomic
force microscopy (AFM), and onto 0.15–0.18 mm thick quartz
substrates (SPI supplies 1019T-AB) for Raman spectroscopy.
For SRS fresh media was added, but for AFM and Raman
spectroscopy the media was replaced by Phosphate Buﬀer
Saline which maintained cell viability during measurements.
Oil red O (Sigma O0625) was dissolved in isopropanol, fil-
tered and diluted to 60% working solution with distilled water.
Cells were fixed with 10% formaldehyde (Sigma 47608) for
20 minutes at room temperature and washed twice with PBS.
Lipid droplets were stained by adding Oil red O working solu-
tion for 15 minutes at room temperature, followed by 2
washing steps with distilled water.
2.2 Atomic force microscopy (AFM)
We used an AFM (Bruker Bioscope II) on an inverted microscope,
with a 20× phase contrast objective lens to view cells and the
AFM cantilever tip. A soft cantilever (Bruker MLCT) was mounted
into the AFM, and its sensitivity measured on a glass substrate in
air, enabling measurement of the cantilever tip upward deflection
as a known distance in nanometres. The tip was then retracted
from the surface, and a power spectrum measured using a soft-
ware module. The area under the fundamental vibrational mode
of the cantilever was equated to the thermal energy to deduce the
cantilever stiﬀness, kc. This enables measurement of the repulsive
force, F, experienced by the cantilever tip by calibrating according
to the equation F = kcZ2, where Z2 is the upward deflection of the
cantilever tip. Living adherent cells were located and the tip apex
positioned above the centre of the nucleus. A ‘force–distance’
curve was then measured by indenting until the force reaches a
given trigger value to avoid damage. The ‘distance’ is the move-
ment of the fixed end of the cantilever, Z1. The indentation depth
of the tip apex into the cell, δ = Z1 − Z2, where Z1 was known and
Z2 was deduced using F = kcZ2.
The cell Elasticity (E), or Young’s Modulus, is extracted
using the Hertz model for a spherical-ended indenter, F =
4/(3[1 − ν2])ER1/2δ3/2 where R is the AFM tip radius (taken as
20 nm for these probes), and ν is the Poisson’s ratio – a measure
of compressibility – taken as 0.37. The Poisson’s ratio of living
cells was measured as 0.36–0.38,40 and 0.37.41 AFM data was
fitted to this Hertz model using the open source software,
AtomicJ.42 Both indentation and retraction Force–distance
curves were acquired sequentially for the same cell.
2.3 Raman spectroscopy
We used a Renishaw InVia Raman microspectroscopy system,
which focusses laser light of wavelength 785 nm into a spot of
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approximate size (FWHM) 2 µm laterally and 20 µm axially, by
under-filling a 0.75 NA phase contrast objective lens (Leica
HCX PL FL 40×/0.75 PH2). The spectral resolution of the
Raman system was measured as 7 cm−1 (FWHM). Raman
spectra were acquired from adherent cells with the laser spot
focussed at the boundary between cytoplasm and nucleus. To
improve the signal to noise ratio, each spectrum was acquired
for 8× 300 s with a laser power of 40 mW measured at the
sample. We acquired phase contrast images before and after
Raman spectroscopy, and observed no changes to the cells. A
background spectrum was acquired by displacing the sample
to a nearby region of bare substrate with no cells, then this
spectrum subtracted from the spectrum of the cell. This
removes the large background signal of the quartz substrate
from the cell spectrum. The laser spot was focussed 2 µm
above the substrate, and this height was not changed while all
cell spectra and background spectra were acquired.
Each spectrum was then processed in several ways: they
were first flattened to remove the eﬀect of cellular autofluore-
scence43 using the small-window moving average automated
baseline correction (SWiMA) procedure. The Matlab code was
kindly provided by the author Schulze. The flattening pro-
cedure iteratively applies a small, but increasing, moving
average window in conjunction with peak stripping to estimate
spectral baselines. Then cosmic ray spikes were removed if
present, using a further automated algorithm by Schulze.44 In
this cosmic ray removal algorithm, individual Raman spectra
from one group (primary or secondary) are compared with
each other. When pixel values (Raman intensities at a given
wavenumber) are more than 3 standard deviations above the
mean, the value is truncated. This process is repeated until the
pixel value is less than 3 standard deviations above the mean.
Resulting spectra were flattened once more with the same pro-
cedure, in case the first flattening procedure was performed on
a spectrum with a cosmic ray. Finally, the maximum intensity
– highest peak in the spectrum – was normalized to unity.
Once processed, principal component analysis (PCA) was per-
formed on an equal number of cells (16 for each group). Each
spectrum can be expressed as a linear combination of other
principal component spectra, αPC1 + βPC2 + γPC3…., and the
scores α and β were plotted on a scatter plot, in order to sepa-
rate out the two groups of cells.
2.4 Stimulated Raman scattering (SRS) microscopy
We employed a home-built multi-photon microscopy system45
adapted for SRS microscopy. This adaptation consists of the
addition of an amplitude modulator (New Focus 4103-01) at
5 MHz to the Stokes beam, and a lock-in amplifier (Stanford
Research SR844) to the detection of transmitted pump beam.
We used 30 mW of each beam, measured at the sample,
delivered by a water-immersion multi-photon objective lens of
numerical aperture 1.05 (Olympus XLPlan N). The resolution
of the system was previously measured as 250 nm FWHM later-
ally and 1.1 µm FWHM axially.34 Stacks of 10 images were
acquired at 1 µm separation, and converted into a 2-dimen-
sional image by Z-projection at maximum intensity to observe
all the lipid droplets throughout the cell. Images had a 61 µs
pixel dwell time, consisted of 512 × 512 pixels, and were aver-
aged 10 times to enhance quality.
3. Results and discussion
3.1 Atomic force microscopy (AFM)
Elasticity values were deduced for a total number of 56
primary cells (SW480) and 45 secondary cells (SW620), and are
plotted in a histogram in Fig. 1. We found the mean values
and standard deviations of elasticity to be 1.39 ± 0.71 kPa
(SW480 retrace) and 0.834 ± 1.43 kPa (SW620 retrace), using
the retraction part of the force–distance curve. Median values
of 1.26 kPa (SW480 retrace) and 0.406 kPa (SW620 retrace)
remove the outliers to oﬀer more representative values for the
cell types, and show that the secondary cells are three times
softer than primary cells. We performed Welch’s t-test on
these elasticity values to determine the likelihood of the null
hypothesis, that both cell types have the same elasticity. This
was rejected and was found to be statistically significant [p =
0.0197]. SW480 cells were previously measured to have an elasti-
city of 0.47 kPa,46 using a tipless cantilever and a model of
the cell as an ellipsoid to extract the elasticity, but no compari-
son was made with SW620 cells. Uncertainty in the AFM canti-
lever’s tip radius R, nominally taken as 20 nm from
manufacturer’s data for the Hertz model, will result in values
which are not absolutely accurate, but relatively accurate when
using the same probe – as was the case in this study. For abso-
lute values of elasticity, a calibration sample is required. 46 of
56 measurements on primary cells have an elasticity greater
than a threshold of 0.70 kPa, and 35 of 45 secondary cells have
an elasticity below this threshold. This corresponds to an accu-
racy of 80% for discriminating cell type by elasticity.
These results compare favourably with previous AFM
measurements which show secondary tumours have lower elasti-
cities (i.e. are softer) than primary tumours from diﬀerent
Fig. 1 Histogram of cell elasticity for primary (SW480) and secondary
(SW620) cancer cells.
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mice,47 and that cells with a high metastatic potential have
lower average elasticities than cells with low metastatic poten-
tial.28,29 However, we are the first to compare primary and
secondary cells from the same organ, or from the same patient.
We are also the first to give a quantitative measure of the accu-
racy of discriminating cell types by this AFM mechanical
measurement.
3.2 Raman spectroscopy
Raman spectra were acquired on 16 individual cells of each
type, SW480 and SW620. The average spectrum for each type,
plotted in Fig. 2, shows significant changes. The diﬀerence
spectrum (SW620 minus SW480) highlights the biochemical
diﬀerences between the two cell types. These biochemical
diﬀerences are presented in Table 1, according to assignment
of the peaks in the Raman spectrum to classes of biomole-
cule.48 Broadly speaking, these suggest that the SW620 cells
contain a higher proportion of porphyrins and beta-sheet pro-
teins than SW480 cells, and SW480s contain a higher pro-
portion of lipids and alpha-helix proteins than SW620s. The
increased concentration of porphyrins in tumours was first
revealed in 1923 49 and these molecules are also autofluore-
scent in the red part of the spectrum so can be detected by
imaging.50 We also compared unnormalised spectra, which
showed similar spectral diﬀerences and essentially the same
biochemical diﬀerences as those presented in Fig. 2 and
Table 1. Ratios of normalised or unnormalised spectra also
demonstrated the same positive and negative peaks as those in
Fig. 2 and Table 1.
Principal Component Analysis (PCA) was used to see how
well individual cells could be distinguished by Raman spectro-
scopy. PCA reduces the diﬀerences in spectra between all 32
cells in the study, to just two variables. In Fig. 3, each spec-
trum from an individual cell is plotted as a separate data
point. It is clear that all the cells could be identified clearly as
SW480 or SW620 just by noting their position on the plot.
When an unknown cell is probed by Raman spectroscopy, it
can be plotted onto the same figure and easily characterized as
SW480 or SW620, with an accuracy approaching 100%. When
we randomly selected 11 of each cell type to create a training
set, the remaining 10 cells were used as a test set and were all
correctly identified when superimposed onto the training
set PCA plot, with the resulting plot appearing very similar to
Fig. 3.
The only other Raman study to compare metastatic and
non-metastatic cell lines was performed over the range
2820–3030 cm−1, which is populated only by C–H bonds, and
only produced partial discrimination using PCA.17
Fig. 2 Average Raman spectra for primary (SW480) and secondary
(SW620) cell lines. The diﬀerence spectrum (oﬀset for clarity) is the
spectrum for SW620 minus the spectrum for SW480.
Table 1 Assignment of vibrational modes48 in the diﬀerence Raman
spectrum in Fig. 2
Raman frequency
(wavenumbers, cm−1)
Biomolecules more
abundant in SW480
621 Phenylalanine
642 Phenylalanine
854 Phenylalanine
1002 Phenylalanine
1031 Phenylalanine
1445 Lipids
1660 α-helix proteins
Raman frequency
(wavenumbers, cm−1)
Biomolecules more
abundant in SW620
752 Porphyrins
1520 Porphyrins
1551 Porphyrins
1622 Porphyrins
1676 β-sheet proteins
Fig. 3 Principal Component Analysis (PCA) plot of Raman spectra for
16 individual cells of each type (SW480 in black, SW620 in red). Clear
separation is observed between the two groups, demonstrating the
eﬀectiveness of Raman spectroscopy to characterize unknown cells as
one or other type.
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3.3 Stimulated Raman scattering (SRS) microscopy
We performed SRS microscopy to image the concentration of
CH2 groups, and imaged three types of sample in Fig. 4. As
well as the purely SW480 and SW620 samples, we also imaged
a mixture of these cell types plated the previous day. Images of
CH2 bonds are dominated by lipids due to the high proportion
of these groups in lipids, compared to other biomolecules.
The SW480s are usually larger than the SW620s, and can be
seen in the mixed sample both due to their size and the far
smaller number of lipid droplets.
Combining the results of Raman spectroscopy and SRS
microscopy, we deduced that although the SW480 cells have a
higher proportion of lipids in than SW620 cells, there are
more lipid droplets – which are predominantly triglycerides51
– in the SW620 cells. This is supported by a previous obser-
vation that there is a dramatic increase in the amount of tri-
glycerides in SW620 compared to SW480 cells.52 The only Raman
study of metastatic and non-metastatic cell lines17 was incon-
clusive about the amount and type of lipids in metastatic cells,
but suggested a higher likelihood of lipid droplets in stained
metastatic cells. The relative abundances of lipid droplets in
both cell types is confirmed by Oil red O staining of fixed cells
in Fig. 5.
4. Conclusion
Three techniques were presented for analysis of living human
primary and secondary tumour cells. All techniques are label-
free, non-destructive and applied to individual cells. Crucially,
SW480 and SW620 cell lines are from the same patient and the
same organ. This removed all unwanted variations and reveal-
ing only the primary or secondary nature of the cells. All other
comparisons either involve diﬀerent organs, diﬀerent patients,
or unrelated cell lines.
A good deal of physical and biochemical information was
revealed about the diﬀerences between primary & secondary
cells. This assumes that the diﬀerences observed for one
patient, are also observed for other patients, and that diﬀer-
ences between cells in vitro are observed in tissue samples.
Further work is required to prove this. Secondary (metastatic)
cells are softer, are smaller, have far more porphyrins and
lipid droplets, but have a lower proportion of lipids and struc-
tural proteins than primary tumour cells.
We also distinguished between cell types using these three
analytical methods, enabling all three techniques as methods
for diagnosis in humans of primary or secondary tumour. All
techniques can be applied to excised tissue from surgery, to
Fig. 4 Stimulated Raman Scattering (SRS) images, acquired at a frequency of 2930 cm−1 (speciﬁc to the CH2 anti-symmetric stretch, dominated by
lipids). All three images are maximum intensity Z-projections, from volume stacks of size 200 × 200 × 10 µm into two-dimensional images of size
200 × 200 µm.
Fig. 5 Transmitted light images of primary (SW480, left) and secondary (SW620, right) tumour cells stained with the lipophilic dye, Oil red O. Red
staining conﬁrms the presence of high levels of lipid droplets in the secondary tumour cells. Image sizes are 120 × 90 µm.
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biopsy or fine needle aspirates, or modified to application
in vivo during surgery – without the requirement to fix, slice,
treat or stain the sample. SRS microscopy and Raman spectro-
scopy can also be used in vivo beneath the surface of tissue.
Acknowledgements
Dimitrios Tsikritsis has a PhD studentship which is funded by
the EPSRC. We would like to thank Rabah Mouras for advice
on SRS microscopy and AFM. No potential conflicts of interest
were disclosed. There are no financial disclosures from any
authors.
References
1 C. L. Chaﬀer and R. A. Weinberg, A Perspective on Cancer
Cell Metastasis, Science, 2011, 331, 1559–1564.
2 A. Fishman, E. Shalom-Paz, M. Fejgin, E. Gaber, M. Altaras
and A. Amiel, Comparing the genetic changes detected in
the primary and secondary tumor sites of ovarian cancer
using comparative genomic hybridization, Int. J. Gynecol.
Cancer, 2005, 15, 261–266.
3 S. Noguchi, K. Motomura, H. Inaji, S. Imaoka and
H. Koyama, Diﬀerentiation of primary and secondary
breast cancer with clonal analysis, Surgery, 1994, 115, 458–
462.
4 M. T. Weigel and M. Dowsett, Current and emerging bio-
markers in breast cancer: prognosis and prediction,
Endocr.-Relat. Cancer, 2010, 17, R245–R262.
5 K. Sukhdeo, R. I. Paramban, J. G. Vidal, J. Elia, J. Martin,
M. Rivera, D. R. Carrasco, A. Jarrar, M. F. Kalady,
C. T. Carson, R. Balderas, A. B. Hjelmeland, J. D. Lathia
and J. N. Rich, Multiplex Flow Cytometry Barcoding and
Antibody Arrays Identify Surface Antigen Profiles of
Primary and Metastatic Colon Cancer Cell Lines, PLoS One,
2013, 8, e53015.
6 C. V. Raman and K. S. Krishnan, A New Type of Secondary
Radiation, Nature, 1928, 121, 501–502.
7 I. Notingher, S. Verrier, H. Romanska, A. E. Bishop,
J. M. Polak and L. L. Hench, In situ characterisation of
living cells by Raman spectroscopy, Spectroscopy, 2002, 16,
43–51.
8 A. Downes and A. Elfick, Raman Spectroscopy and Related
Techniques in Biomedicine, Sensors, 2010, 10, 1871–1889.
9 R. Thomas, K. A. Bakeev, M. Claybourn and R. Chimenti,
The Use of Raman Spectroscopy in Cancer Diagnostics,
Spectroscopy, 2013, 28, 36–43.
10 A. Mahadevan-Jansen and R. Richards-Kortum, Raman
spectroscopy for cancer detection: a review, in Engineering
in Medicine and Biology Society, Proceedings of the 19th
Annual International Conference of the IEEE, 1997, IEEE,
1997, 2722–2728.
11 A. Nijssen, T. C. Bakker Schut, F. Heule, P. J. Caspers,
D. P. Hayes, M. H. A. Neumann and G. J. Puppels, Discrimi-
nating Basal Cell Carcinoma from its Surrounding Tissue by
Raman Spectroscopy, J. Invest. Dermatol., 2002, 119, 64–69.
12 P. Caspers, G. Lucassen and G. Puppels, Combined in vivo
confocal Raman spectroscopy and confocal microscopy of
human skin, Biophys. J., 2003, 85, 572–580.
13 C. Kendall, M. Isabelle, F. Bazant-Hegemark, J. Hutchings,
L. Orr, J. Babrah, R. Baker and N. Stone, Vibrational
spectroscopy: a clinical tool for cancer diagnostics, Analyst,
2009, 134, 1029–1045.
14 A. S. Haka, K. E. Shafer-Peltier, M. Fitzmaurice, J. Crowe,
R. R. Dasari and M. S. Feld, Diagnosing breast cancer by
using Raman spectroscopy, Proc. Natl. Acad. Sci. U. S. A.,
2005, 102, 12371–12376.
15 M. D. Keller, E. M. Kanter and A. Mahadevan-Jansen,
Raman Spectroscopy for Cancer Diagnosis, Spectroscopy,
2006, 21.
16 N. Santana, C. Nieva, A. Sierra, M. Marro, S. Rao and
D. Petrov, Raman microspectroscopy is a tool to identify
the metastatic ability of breast tumors, in BioPhotonics,
2011 International Workshop on, 2011, 1–3.
17 C. Nieva, M. Marro, N. Santana-Codina, S. Rao, D. Petrov
and A. Sierra, The Lipid Phenotype of Breast Cancer Cells
Characterized by Raman Microspectroscopy: Towards a
Stratification of Malignancy, PLoS One, 2012, 7, e46456.
18 M. Hedegaard, C. Kraﬀt, H. J. Ditzel, L. E. Johansen,
S. Hassing and J. Popp, Discriminating isogenic cancer
cells and identifying altered unsaturated fatty acid content
as associated with metastasis status, using k-means cluster-
ing and partial least squares-discriminant analysis of
Raman maps, Anal. Chem., 2010, 82, 2797–2802.
19 A. F. d. Oliveira, I. D. d. A. O. Santos, S. B. Cartaxo,
R. A. Bitar, M. M. S. e. S. Enokihara, H. d. S. Martinho,
A. A. Martin and L. M. Ferreira, Diﬀerential diagnosis in
primary and metastatic cutaneous melanoma by FT-Raman
spectroscopy, Acta Cirurgica Brasileira, 2010, 25, 434–439.
20 M. Tollefson, J. Magera, T. Sebo, J. Cohen, A. Drauch,
J. Maier and I. Frank, Raman spectral imaging of prostate
cancer: can Raman molecular imaging be used to augment
standard histopathology?, BJU Int., 2010, 106, 484–488.
21 G. R. Lloyd, L. E. Orr, J. Christie-Brown, K. McCarthy,
S. Rose, M. Thomas and N. Stone, Discrimination between
benign, primary and secondary malignancies in lymph
nodes from the head and neck utilising Raman spectro-
scopy and multivariate analysis, Analyst, 2013, 138, 3900–
3908.
22 G. Binnig, C. F. Quate and C. Gerber, Atomic Force Micro-
scope, Phys. Rev. Lett., 1986, 56, 930–933.
23 M. Radmacher, R. Tillamnn, M. Fritz and H. Gaub, From
molecules to cells: imaging soft samples with the atomic
force microscope, Science, 1992, 257, 1900–1905.
24 J. Domke and M. Radmacher, Measuring the Elastic Pro-
perties of Thin Polymer Films with the Atomic Force Micro-
scope, Langmuir, 1998, 14, 3320–3325.
25 E. C. Sarah, J. Yu-Sheng, T. Julianne, W. Roger, R. JianYu
and K. G. James, AFM-based analysis of human metastatic
cancer cells, Nanotechnology, 2008, 19, 384003.
Analyst Paper
This journal is © The Royal Society of Chemistry 2015 Analyst, 2015, 140, 5162–5168 | 5167
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
5 
Ju
ne
 2
01
5.
 D
ow
nl
oa
de
d 
on
 1
4/
01
/2
01
6 
16
:4
4:
22
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
26 S. E. Cross, Y.-S. Jin, J. Rao and J. K. Gimzewski, Nano-
mechanical analysis of cells from cancer patients, Nat
Nanotechnol., 2007, 2, 780–783.
27 M. Plodinec, M. Loparic, C. A. Monnier, E. C. Obermann,
R. Zanetti-Dallenbach, P. Oertle, J. T. Hyotyla, U. Aebi,
M. Bentires-Alj, Y. H. LimRoderick and C.-A. Schoenenberger,
The nanomechanical signature of breast cancer, Nat Nano-
technol., 2012, 7, 757–765.
28 W. Xu, R. Mezencev, B. Kim, L. Wang, J. McDonald and
T. Sulchek, Cell stiﬀness is a biomarker of the metastatic
potential of ovarian cancer cells, PLoS one, 2012, 7, e46609.
29 Z. Zhou, C. Zheng, S. Li, X. Zhou, Z. Liu, Q. He, N. Zhang,
A. Ngan, B. Tang and A. Wang, AFM nanoindentation
detection of the elastic modulus of tongue squamous carci-
noma cells with diﬀerent metastatic potentials, Nano-
medicine, 2013, 9, 864–874.
30 K. Kong, C. J. Rowlands, S. Varma, W. Perkins, I. H. Leach,
A. A. Koloydenko, H. C. Williams and I. Notingher, Diag-
nosis of tumors during tissue-conserving surgery with inte-
grated autofluorescence and Raman scattering microscopy,
Proc. Natl. Acad. Sci. U. S. A., 2013, 110, 15189–15194.
31 N. D. Magee, J. R. Beattie, C. Carland, K. McManus,
I. Bradbury, D. A. Fennell, M. Ennis, J. J. McGarvey,
J. S. Elborn, P. W. Hamilton and R. Davis, Raman microscopy
in the diagnosis and prognosis of surgically resected non-
small cell lung cancer, J. Biomed. Opt., 2010, 15, 026015.
32 A. Zumbusch, G. R. Holtom and X. S. Xie, Three-Dimen-
sional Vibrational Imaging by Coherent Anti-Stokes Raman
Scattering, Phys. Rev. Lett., 1999, 82, 4142–4145.
33 C. W. Freudiger, W. Min, B. G. Saar, S. Lu, G. R. Holtom,
C. He, J. C. Tsai, J. X. Kang and X. S. Xie, Label-free bio-
medical imaging with high sensitivity by stimulated
Raman scattering microscopy, Science, 2008, 322, 1857–
1861.
34 R. Mouras, G. Rischitor, A. Downes, D. Salter and A. Elfick,
Nonlinear optical microscopy for drug delivery monitoring
and cancer tissue imaging, J. Raman Spectrosc., 2010, 41,
848–852.
35 R. Mouras, P. Bagnaninchi, A. Downes and A. Elfick, Multi-
modal, label-free nonlinear optical imaging for appli-
cations in biology and biomedical science, J. Raman
Spectrosc., 2013, 44, 1373–1378.
36 T. T. Le, T. B. Huﬀ and J.-X. Cheng, Coherent anti-Stokes
Raman scattering imaging of lipids in cancer metastasis,
BMC Cancer, 2009, 9, 42.
37 R. Mitra, O. Chao, Y. Urasaki, O. B. Goodman and T. T. Le,
Detection of lipid-rich prostate circulating tumour cells
with coherent anti-Stokes Raman scattering microscopy,
BMC Cancer, 2012, 12, 540.
38 X. S. Xie, C. W. Freudiger, D. A. Orringer, B. G. Saar, M. Ji,
Q. Zeng, L. Ottoboni, W. Ying, C. Waeber and J. R. Sims,
Multicolored Stain-Free Histopathology with Coherent
Raman Imaging, Lab. Invest., 2012, 92, 1492–1502.
39 R. E. Hewitt, A. McMarlin, D. Kleiner, R. Wersto, P. Martin,
M. Tsokos, G. W. Stamp and W. G. Stetler-Stevenson, Vali-
dation of a model of colon cancer progression, J. Pathol.,
2000, 192, 446–454.
40 W. R. Trickey, F. P. T. Baaijens, T. A. Laursen,
L. G. Alexopoulos and F. Guilak, Determination of the Pois-
son’s ratio of the cell: recovery properties of chondrocytes
after release from complete micropipette aspiration,
J. Biomech., 2006, 39, 78–87.
41 D. Shin and K. Athanasiou, Cytoindentation for obtaining
cell biomechanical properties, J. Orthop. Res., 1999, 17,
880–890.
42 P. Hermanowicz, M. Sarna, K. Burda and H. Gabryś,
AtomicJ: An open source software for analysis of force
curves, Rev. Sci. Instrum., 2014, 85, 063703.
43 H. G. Schulze, R. B. Foist, K. Okuda, A. Ivanov and
R. F. B. Turner, A Small-Window Moving Average-Based
Fully Automated Baseline Estimation Method for Raman
Spectra, Appl. Spectrosc., 2012, 66, 757–764.
44 H. G. Schulze and R. F. B. Turner, A Fast, Automated, Poly-
nomial-Based Cosmic Ray Spike Removal Method for the
High-Throughput Processing of Raman Spectra, Appl. Spec-
trosc., 2013, 67, 457–462.
45 A. Downes, R. Mouras and A. Elfick, A versatile CARS micro-
scope for biological imaging, J. Raman Spectrosc., 2009, 40,
757–762.
46 O. Jonas, C. T. Mierke and J. A. Kas, Invasive cancer cell
lines exhibit biomechanical properties that are distinct
from their noninvasive counterparts, Soft Matter, 2011, 7,
11488–11495.
47 M. Plodinec, M. Loparic, C. A. Monnier, E. C. Obermann,
R. Zanetti-Dallenbach, P. Oertle, J. T. Hyotyla, U. Aebi,
M. Bentires-Alj and R. Y. Lim, The nanomechanical signa-
ture of breast cancer, Nat. Nanotechnol., 2012, 7, 757–765.
48 Z. Movasaghi, S. Rehman and I. U. Rehman, Raman Spec-
troscopy of Biological Tissues, Appl. Spectrosc. Rev., 2007,
42, 493–541.
49 A. Policard, A study on the available aspects of experi-
mental tumours examined by Wood’s light, C. R. Seances
Soc. Biol. Ses Fil., 1924, 91, 1423–1424.
50 M. Hefti, H. Maximilian Mehdorn, I. Albert and L. Dorner,
Fluorescence-Guided Surgery for Malignant Glioma: A
Review on Aminolevulinic Acid Induced Protoporphyrin IX
Photodynamic Diagnostic in Brain Tumors, Curr. Med.
Imaging Rev., 2010, 6, 254–258.
51 F. Baenke, B. Peck, H. Miess and A. Schulze, Hooked on
fat: the role of lipid synthesis in cancer metabolism and
tumour development, Dis. Models & Mech., 2013, 6, 1353–
1363.
52 C. J. Fhaner, S. Liu, H. Ji, R. J. Simpson and G. E. Reid,
Comprehensive Lipidome Profiling of Isogenic Primary
and Metastatic Colon Adenocarcinoma Cell Lines, Anal.
Chem., 2012, 84, 8917–8926.
Paper Analyst
5168 | Analyst, 2015, 140, 5162–5168 This journal is © The Royal Society of Chemistry 2015
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
5 
Ju
ne
 2
01
5.
 D
ow
nl
oa
de
d 
on
 1
4/
01
/2
01
6 
16
:4
4:
22
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
